Lecanemab-irmb in Real-World Use for Alzheimer’s Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, postmarketing effort using ALZ-NET data to monitor safety signals associated with lecanemab-irmb in patients diagnosed with Alzheimer's disease. The study tracks events such as ARIA (edema and hemosiderin deposition), symptomatic ARIA, intracerebral hemorrhage, seizures, anaphylaxis, CNS ischemic events, and death in a real-world setting. It will also examine how safety outcomes vary with factors like APOE genotype, MRI signs of cerebral amyloid angiopathy risk, prior Alzheimer’s treatments, and antithrombotic use. No new treatment is administered as part of the study; data are drawn from existing clinical practice. The project leverages the ALZ-NET registry, which includes a large cohort of patients evaluated for or treated with new FDA-approved AD therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Enrolled in ALZ-NET
* Either currently receiving or previously received lecanemab-irmb.

Exclusion Criteria:

-None

Where it's running

• Eisai Trial Site #1
  Nutley, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Eisai Medical Information
• Email: esi_medinfo@eisai.com
• Phone: +1-888-274-2378

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lecanemab in Early to Moderate Alzheimer's Disease using Multi-omics data

  This study tests whether Lecanemab can help people with early-to-moderate Alzheimer's disease and uses multiple biological data types to understand its effects.

  Recruiting Phase 4 First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07604896

• Observing the effects of lecanemab in early Alzheimer's disease patients

  This study looks at how lecanemab affects early Alzheimer's patients and what happens to them if they experience certain side effects while on the treatment.

  Recruiting at 3 sites Eisai Inc. · Hiroshima and 2 other locations · NCT06322667

• Acoustic Stimulation During Sleep for Alzheimer’s Disease

  Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07924657

• FAME: A Italian test to recognize famous faces and name them

  This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.

  Recruiting at 8 sites Istituti Clinici Scientifici Maugeri SpA · Sciacca, AG and 9 other locations · NCT07911878

• NMS-01 safety test in people with mild to moderate Alzheimer's disease

  This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.

  Recruiting Neumous Inc. · Seoul, Seodaemun · NCT07869238

• Choose Myself (Before) Losing Myself

  We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07846566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.